Cargando…
Treatment-Induced Bone Loss and Fractures in Cancer Patients Undergoing Hormone Ablation Therapy: Efficacy and Safety of Denosumab
Hormone ablation therapy (HALT) for breast or prostate cancer accelerates the development of osteoporosis in both men and women by causing estrogen deficiency, which increases the risk for fracture by promoting bone resorption mediated by osteoclasts. Denosumab, a fully human monoclonal antibody tha...
Autores principales: | Lipton, Allan, Smith, Matthew R., Ellis, Georgiana K., Goessl, Carsten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3427033/ https://www.ncbi.nlm.nih.gov/pubmed/22933844 http://dx.doi.org/10.4137/CMO.S8511 |
Ejemplares similares
-
Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Rader, Michael, et al.
Publicado: (2012) -
Effect of risedronate on bone loss at discontinuation of denosumab
por: Laroche, Michel, et al.
Publicado: (2020) -
Safety and efficacy of denosumab in the treatment of pulmonary metastatic giant cell tumor of bone
por: Luo, Yi, et al.
Publicado: (2018) -
Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
por: Chen, Yi, et al.
Publicado: (2021) -
Effects of bone turnover status on the efficacy and safety of denosumab among haemodialysis patients
por: Hori, Mayuko, et al.
Publicado: (2022)